I think part of the problem in how we're evaluating the literature and evaluating the outcomes is with the outcome that's actually being looked at within the clinical trials. That may be what misleads the population.
We're not looking at hard end evidence; we're looking at what we refer to as surrogate markers. We look at a decrease in blood pressure as being an efficacy, with a blood pressure medication, for instance. But do we know whether that in fact is going to translate into decreased death at the end of the day?
That's what we're not looking at. I think with post-marketing surveillance we can start collecting this information, analyzing the data, and seeing whether indeed our patients are doing better at the end of the day. We're missing out on that end. Unless we have somebody who then takes on the role of doing that post-market surveillance or does a phase four with that intent as an outcome, we never know whether we're treating with a drug that really is going to have a benefit.